Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, talks about the importance of a patient receiving genetic counseling after an ovarian cancer diagnosis.
Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, talks about the importance of a patient receiving genetic counseling after an ovarian cancer diagnosis.
Transcript:
Why is genetic counseling so important after a patient is diagnosed with ovarian cancer?
Thank you for asking this question I think this is really, really important. A lot of patients and providers don't realize that ovarian cancer has a huge genetic component as far as the causes of it. About 20% of women who are diagnosed with an ovarian cancer actually have a gene mutation that caused it. When I say gene mutation, I mean something that they inherited, something that they could potentially pass onto their children, or be sharing with a sibling.
Ovarian cancer is one of the most lethal cancers that a woman can be diagnosed with. In fact, 75% of the time it's diagnosed at an advanced stage. We don't have a screening test for it so picking it up early is really by luck or by chance. In women who are diagnosed with advanced stage, the liklihood of them being alive at 5 years is around 60%— again, that is because this is a highly lethal disease.
Women who are diagnosed with an ovarian cancer should be seen by a genetic counselor. Basically what will happen when they're seen by a genetic counselor is that the genetic counselor will go through their family history, personal history, and look for other signs that may indicate a genetic mutation that caused the cancer.
So, ovarian cancer tends to travel with breast cancer, so it's important for women to know that a strong family history of breast and/or ovarian cancer should prompt genetic counseling. The National Comprehensive Cancer Network [NCCN] basically has guidelines for when women should be referred for genetic counseling. A personal diagnosis of ovarian cancer is all you need to be recommended for genetic counseling.
The Society of Gynecologic Oncology also has a statement supporting the fact that women should be referred for genetic counseling if they have this diagnosis. At Mayo Clinic, in 2015, we looked at our genetic counseling referral rates for women with ovarian cancer diagnosis. It was a quality improvement project actually, and we defined what our current rate was, and it was 20%. Which really— we weren't compliant then essentially with NCCN guidelines. And so we implemented a bundled approach that included patient education, order sets and referral guideline implementation into the electronic medical record for each woman diagnosed with ovarian cancer.
Patient education— not just through check lists of risks factors but also education in the form of a short video that they watched in the hospital after their surgery. What we were able to do is we were able to increase our rates of referral from our pre or historic referral rate which by the time we implemented the project we actually moved the needle a little bit already, we were at 40% referral. But with our quality improvement project, we actually went up to 77% referral rate.
So, we're continuing to try to refine that because ideally we do want to chase 100% because all of these women really should be seen for genetic counseling and offered genetic testing.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More